Description
ASH Annual Meeting
Gene Therapy + Immunotherapy
Late-Breaking Updates
2025 Edition
Gene Therapy + Immunotherapy
Late-Breaking Updates
2025 Edition
ASH 2025: The 67th Annual Meeting & Exposition (On-Demand)
The “Super Bowl” of hematology—where practice-changing data becomes the next decade’s standard of care.
This 2025 New Orleans edition defines the logistics of cure: commercial gene editing, real-world cellular therapy delivery,
and high-yield malignant and non-malignant hematology updates.
🗓️ Dates: December 6–9, 2025
| 📍 Location: New Orleans, Louisiana (Ernest N. Morial Convention Center)
| 💲 Price: $150
| 📍 Location: New Orleans, Louisiana (Ernest N. Morial Convention Center)
| 💲 Price: $150
Access & Delivery (Important)
- Google Drive access (downloadable files)
- Unlimited access — keep your materials permanently
- Recommended: download files first for the smoothest viewing experience
Bundle & Save (Always On)
Add 2 or more courses and get an instant 15% OFF — unlimited use, no expiration.
Format
Scientific Plenary + Education
Plus satellite symposia highlights
Scope
Malignant + Non-Malignant
~70% malignant / ~30% benign + coag
Why It Matters
Practice-Changing Data
Algorithms, pathways, and real-world delivery
General Information
Welcome to the global benchmark in blood. ASH is where the most important hematology data is released—then rapidly translated
into the next standard of care. The 2025 New Orleans meeting marks a pivotal shift from “experimental” gene editing to
commercial reality—making implementation, referral pathways, toxicity management, and long-term follow-up as important as the science.
This on-demand curriculum emphasizes practical clinical decision-making across malignant hematology (myeloma, lymphoma, AML/MDS)
and non-malignant hematology (red cell disorders, coagulation), with a dedicated focus on cellular therapy logistics and toxicity protocols.
Target Audience
- Hematologist-Oncologists making therapy choices between bispecifics vs CAR-T, sequencing BCMA targets, and chemo-free standards
- Pathologists integrating AI-driven diagnostics and next-gen sequencing into reporting workflows
- Transplant/Cellular Therapy Physicians managing CRS/ICANS and outpatient toxicity pathways
- Hospitalists/General Clinicians recognizing hematologic emergencies and caring for long-term gene-therapy survivors
Learning Objectives
- Revolutionize myeloma care: apply 2025 algorithms for quadruplet therapy and sequence BCMA-targeted agents in relapse
- Implement gene editing: navigate referral and management pathways for gene therapy in sickle cell disease and beta-thalassemia
- Target AML with precision: incorporate menin inhibitors for KMT2A-rearranged and NPM1-mutated AML
- Modernize hemophilia care: transition from factor replacement to gene therapy and non-factor replacement strategies
Course Topics & Tracks (2025 High-Yield Focus)
Topic 1: Myeloma & Lymphoma Revolution
- Bispecifics vs CAR-T: choosing “off-the-shelf” antibodies vs autologous cell therapy
- BCMA sequencing strategies in relapse
- MCL & CLL: chemo-free combinations (BTK + BCL2) moving to first-line standards
Topic 2: Leukemia & Myeloid Malignancies
- AML triplet concepts for unfit patients (HMA + venetoclax + novel agent)
- Menin inhibitors for molecular AML subsets
- MDS: mastering WHO vs ICC and molecularly defined risk
Topic 3: Non-Malignant Hematology
- Sickle cell “cure” logistics: safety, fertility, and long-term follow-up
- ITP/TTP: complement pathways and FcRn inhibition
- Coagulation updates with practical clinical pathways
Topic 4: Immuno-Oncology & Toxicity Management
- CRS/ICANS protocols that preserve safety without automatic ICU admission
- Infection prevention strategies during profound immunosuppression
- Outpatient cellular therapy monitoring and escalation pathways
Related Courses
FAQ
What makes ASH 2025 different from other hematology updates?
ASH is the primary venue for late-breaking, practice-changing hematology data. The 2025 edition emphasizes real-world implementation of gene therapy and cellular therapy alongside major malignant and non-malignant updates.
Is this useful if I don’t do cellular therapy?
Yes. The curriculum covers broad malignant hematology (myeloma/lymphoma/AML/MDS) plus non-malignant and coagulation updates, with practical decision pathways relevant to general hematology and inpatient consult work.
How do I receive access?
You will receive Google Drive access with unlimited downloadable files.
How should I study ASH 2025 efficiently?
Start with plenary/late-breaking updates, then focus on your daily practice track (myeloma/lymphoma, AML/MDS, benign red cell/coag). Pair it with a board review or QBank from Related Courses to lock in algorithms and sequencing decisions.
Student & Physician Experiences
David M., Hematologist-Oncologist
★★★★★
The myeloma sequencing insights and toxicity pathways were immediately applicable—especially bispecific vs CAR-T decision points.
Sarah L., Hematology Fellow
★★★★★
Great synthesis of late-breaking updates. Helped me build a clean study plan across AML/MDS and benign heme.
James P., Hospitalist
★★★★★
Clear clinical framing of emergencies and referral pathways—perfect for inpatient consult support and post-gene-therapy follow-up.
Olivia K., Pathologist
★★★★★
Loved the emphasis on molecular classification and workflow integration—very relevant for modern diagnostic reporting.
